IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by PKO Investment Management Joint Stock Co

PKO Investment Management Joint Stock Co boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,300 shares of the company's stock after purchasing an additional 500 shares during the period. PKO Investment Management Joint Stock Co's holdings in IDEXX Laboratories were worth $1,386,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $30,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. boosted its position in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Leerink Partners upped their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Stifel Nicolaus upped their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a research report on Monday, May 19th. Finally, Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $546.00.

IDEXX Laboratories Stock Down 0.1%

Shares of IDXX stock traded down $0.74 during trading hours on Thursday, hitting $519.85. 590,930 shares of the company were exchanged, compared to its average volume of 649,057. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.73. The business's 50-day simple moving average is $484.15 and its two-hundred day simple moving average is $447.01. The stock has a market capitalization of $41.81 billion, a price-to-earnings ratio of 48.05, a P/E/G ratio of 3.80 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, topping the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The business had revenue of $998.43 million for the quarter, compared to analysts' expectations of $998.25 million. During the same quarter last year, the company posted $2.71 earnings per share. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This trade represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.98% of the stock is currently owned by corporate insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.